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Abstract
Inflammatory cytokines are key drivers of cartilage degradation in post-traumatic osteoar-
thritis. Cartilage degradation mediated by these inflammatory cytokines has been exten-
sively investigated using in vitro experimental systems. Based on one such study, we have
developed a computational model to quantitatively assess the impact of charged small mol-
ecules intended to inhibit IL-1 mediated cartilage degradation. We primarily focus on the
simplest possible computational model of small molecular interaction with the IL-1 system—
direct binding of the small molecule to the active site on the IL-1 molecule itself. We first use
the model to explore the uptake and release kinetics of the small molecule inhibitor by carti-
lage tissue. Our results show that negatively charged small molecules are excluded from
the negatively charged cartilage tissue and have uptake kinetics in the order of hours. In
contrast, the positively charged small molecules are drawn into the cartilage with uptake
and release timescales ranging from hours to days. Using our calibrated computational
model, we subsequently explore the effect of small molecule charge and binding constant
on the rate of cartilage degradation. The results from this analysis indicate that the small
molecules are most effective in inhibiting cartilage degradation if they are either positively
charged and/or bind strongly to IL-1α, or both. Furthermore, our results showed that the car-
tilage structural homeostasis can be restored by the small molecule if administered within
six days following initial tissue exposure to IL-1α. We finally extended the scope of the
computational model by simulating the competitive inhibition of cartilage degradation by the
small molecule. Results from this model show that small molecules are more efficient in
inhibiting cartilage degradation by binding directly to IL-1α rather than binding to IL-1α
receptors. The results from this study can be used as a template for the design and develop-
ment of more pharmacologically effective osteoarthritis drugs, and to investigate possible
therapeutic options.
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Introduction
In this paper, we model both IL-1 driven degradation of cartilage explants and the ability of
selected small molecule inhibitors (MW 3 to 10 kDa) to modify this tissue response. Our goal
is to build a quantitative understanding of IL-1 mediated cartilage degradation in the presence
of electrically charged small molecules intended to reduce IL-1 induced cartilage degradation.
To this end, we have developed an extended version of our previously experimentally validated
computational model used for simulating IL-1α mediated degradation of cartilage tissue [1].
Our previous model simulated the transport of IL-1α, the interaction between IL-1α and its
receptors (IL-1R) on the surface of the chondrocytes, secretion of aggrecanases (ADAM-TS4
and ADAM-TS5) and matrix metalloproteinases (MMP-1 and MMP-13) by chondrocytes and
the degradation of aggrecan and collagen [1]. The computational model developed in this
study includes all these biochemical interactions, and the interaction of the small molecule
with IL-1 or its receptor. However, this model also takes into account: (i) the negative fixed
charged on cartilage tissue, (ii) the physiological ionic strength of the support medium (in
vitro)/synovial fluid (in vivo), (iii) the electrical charge on IL-1α and selected drugs (small mol-
ecule inhibitors) and (iv) Donnan partitioning of electrically charged molecules between sup-
port medium/synovial fluid and cartilage tissue. Our primary purpose is to develop a
computation model for analysing experimental data and investigating hypotheses related to
IL-1 driven degradation of cartilage extracellular matrix.
The interleukins comprise a large group of molecules that play key roles in the regulation of
inflammation and innate immunity [2]. Within the interleukins, the IL-1 family of biomolecules
plays a central role [3]. The IL-1 family has many components, including seven pro-inflamma-
tory agonists (IL-1α, IL-1β, IL-18, IL-33, IL-36α, IL-36β and IL-36γ), three receptor antagonists
(IL-1Ra, IL-36Ra, IL-38) and an anti-inflammatory cytokine (IL-37) [3, 4]. The IL-1 family
interacts with the IL-1 receptor (IL-1R) family of biomolecules [4], which itself includes four
signaling receptor complexes, two decoy receptors (IL-1R2, IL-18BP) and two negative regula-
tors (TIR8 or SIGIRR, IL-1RAcPb) [2, 4]. As is usual for most biological signaling systems, the
complexity of this system helps to ensure that the right balance is struck over time between cel-
lular unresponsiveness to an IL-1 signal and excessive amplification of any signal [4].
When a signaling imbalance does lead to excessive inflammation [4], molecular modifiers
are sought that either restrict or enhance interactions within the IL-1 signaling system, which
offer hope of a therapeutic benefit [5, 6]. For example, the most important current inhibitors
of IL-1 signaling include canakinumab (a monoclonal antibody that binds to IL-1β), anakinra
(an IL-1R antagonist), rilanocept (a decoy IL-1α and IL-1β receptor) and gevokizumab (a
monoclonal antibody that allosterically regulates IL-1β) [5, 7, 8]. However, canakinumab, rila-
nocept and gevokizumab are all large molecules (MW = 145–200 kDa) [9–11], which leads to
steric exclusion from some tissues including cartilage—the tissue of interest in this study [12].
In contrast, anakinra has a molecular size similar to IL-1 (MW = 17 kDa) [13], and so it can
access cartilage tissue.
Given the role of inflammatory mediators in driving tissue damage in post-traumatic joint
injury [1, 14, 15], and the possibility that anakinra may significantly modify such inflammatory
states, a single dose pilot intervention clinical trial of anakinra was undertaken on people
within 30 days of post-traumatic knee joint injury [15]. However the clinical trial found no sig-
nificant difference between treatment and control groups across 21 biomarkers measured in
both serum and synovial fluid [15]. The authors concluded that the absence of a statistically
significant outcome was partly attributable to the smaller sampling size of the study (eleven
patients). However, the more important factor was believed to be the short in vivo half-life
of anakinra (four to six hours) following the single intra-articular injection [15, 16]. Most
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importantly, the outcome of this clinical trial designed to modify IL-1 signaling highlights the
importance of first understanding the pharmacokinetics and pharmacodynamics of potential
drugs targeted to particular tissues. Indeed, the computational model described herein is spe-
cifically designed to quantitatively model IL-1 mediated degradation of cartilage in the pres-
ence of a drug that interacts with IL-1 or IL-1R.
Unfortunately, there is very little information in literature about the systematic cataloguing
of these desirable small molecular properties to target specific tissues. In the 1990’s tests were
conducted on very small molecules (MW < 500) to find suitable candidates to block the
actions of IL-1, 2, and 5, but without much success [17]. The failure of these tests was attrib-
uted to the size of the small molecules tested (MW< 500 Da) compared to the target cytokines
and their corresponding receptors (MW = 8 kDa to 80 kDa) [18–20]. Typically, cytokines and
their receptors have a larger ‘interaction surface’, with binding dissociation constants ranging
from 1–100 pM [20]. For example, IL-1 (MW = 17 kDa) interacts with high affinity IL-1 recep-
tors (80 kDa transmembrane glycoprotein) with a dissociation constant ranging from 3–8 pM
[21]. In contrast, ‘high affinity’ small molecules have their affinity restricted by their small
interaction surface, and so their binding dissociation constant typically ranges from 10 to 100
nM [20]. So having comparatively small dissociation constants, at low concentrations most
small molecule antagonists are simply outcompeted by native ligands.
The limitations associated with binding of very small molecules to cytokines or its receptors
has led to a search of somewhat larger molecules (MW>2 kDa), which have correspondingly
larger surface areas and so are more likely to have smaller dissociation constants, and so likely
to be therapeutically effective at lower concentrations. Furthermore, small molecules of MW
greater than 2 kDa of appropriate shape and binding specificity also offer the potential for the
molecule to bind at several spatially discrete sites on the target molecule, particularly if these
molecules involve two or more small molecules joined by a ‘linker’ molecule [22]. It has been
found that acidic polysaccharides bind well to IL-1, the prototypical molecule in this class
being heparin [23, 24]. This has led to a search for glycans that can bind to interleukins. Initial
studies in this area have shown promising results [24]. However, an important issue for highly
sulphated glycans in cartilage tissue is their negative charge. This highlights the importance of
taking into account the Donnan partitioning of any small drug from the synovial fluid into
cartilage in the computational model of cartilage degradation.
For simplicity, in this paper we primarily focus on the simplest possible model of small
molecular interaction with the IL-1 system, that is, direct binding of the small molecule (SM)
to the active site on the IL-1 molecule itself. However, the model is extensible and can be
adjusted to include any modifier of the IL-1 cascade, including competitive binding of the SM
to the active site on the IL-1 receptor, or binding to downstream products of IL-1 system acti-
vation, such as aggrecanases. To illustrate this, here we also change the model so that the SM
binds IL-1R competitively (along with IL-1), rather than binding to IL-1 directly. In the follow-
ing, we first use the model to explore the uptake and release kinetics of a small molecule (MW
3 to 10 kDa) by cartilage tissue. We have selected the molecular weight of the small molecule
based on the reported molecular weights of known osteoarthritis inhibitors including sodium/
calcium pentosan polysulfate (PPS) [25–27], IGF-1 [28, 29], glucosamine sulfate [30, 31] and
chondroitin sulfate [32, 33]. However should the need arise, transport of larger molecules
could be modelled by taking into account steric exclusion. We then model the direct interac-
tion of the small molecule with IL-1α, and use the model to predict changes in the rate of carti-
lage degradation depending on both charge and binding affinity. Then we use the model to
explore the effects of changes in the timing of therapeutic intervention following elevation of
IL-1α as observed during the early stages of post-traumatic osteoarthritis [15]. Finally, we con-
sider the inhibition of IL-1α mediated cartilage degradation by competition between IL-1α
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and SM for the binding site on IL-1R. We find that for the same binding constant, the SM is
much less effective at inhibiting cartilage degradation when the SM competitively inhibits IL-
1R than when it binds directly to IL-1α.
Materials and Methods
Model Description
We develop a computational model to simulate the biochemical interaction of a small charged
drug molecule (molecular weight assumed to be about 3 to 10 kDa) with articular cartilage tis-
sue, taking into account the charge on the molecule, with valencies ranging from -16 to +16.
We have selected the molecular weight and charge range of the small molecule based on values
reported in literature for known osteoarthritis (OA) inhibitors including sodium/calcium pen-
tosan polysulfate (PPS) [25–27], IGF-1 [12, 28, 34], glucosamine sulfate [30, 31] and chondroi-
tin sulfate [32, 33, 35]. The model accounts for cation inclusion and anion exclusion in
equilibrium for a given negative fixed charge in cartilage. We first use the model to simulate
the IL-1α mediated cartilage degradation process. Subsequently, we use the model to demon-
strate the kinetics of non-equilibrium transport of the small molecule into cartilage, and we
calculate the equilibration time for sorption and desorption of the small molecule in cartilage.
We then link this drug model to an IL-1 mediated cartilage degradation model and simulate
IL-1 inhibition by the small molecule.
The cartilage degradation model is based on our earlier model of IL-1α mediated biochemi-
cal degradation of bovine calf cartilage tissue explants [1], modified to account for the trans-
port of charged species, including sodium ions (Na+), chloride ions (Cl-), IL-1α and a small
charged molecule (SM). The complete model accounts for the kinetics of the chemical interac-
tion between IL-1α and the SM. We first calibrate the model by setting the net charge on IL-1α
to -1, and first assume no chemical interaction between IL-1α and the SM. The magnitude of
the net charge on IL-1 is selected based on the reported IL-1α isoelectric point (pI) of 6 [36]
and assuming a neutral pH of 7.0 (i.e. approximately physiological pH). We then model the
equilibrium distribution of the small molecules within cartilage tissue for various net charges
on the small molecule. We select net charge magnitudes ranging from -16 to +16. The average
basal fixed charge within the cartilage is assumed to be -0.2 mmoles/g of cartilage [37], but the
fixed charge is allowed to vary with depth of the cartilage tissue based on the reported in vivo
depth based variation in aggrecan concentration [1, 38, 39]. For these simulations, we first
assume that there is no chemical interaction between the SM and IL-1α. This simulation dem-
onstrates how the electrical charge of the small molecule mediates its sorption and desorption
kinetics, independent of any binding interactions. We then extend this model to simulate the
uptake and release of positively charged small molecule (SM) by cartilage tissue, taking into
account the binding of the molecule to the cartilage ECM, as reported previously [12, 40].
Next we model the inhibitory action of the SM on the biochemical degradation of the
cartilage tissue, based on enabling chemical interactions between IL-1α and the SM. The
degradation of cartilage is monitored by the release of aggrecan from the cartilage to the sur-
rounding media. This analysis is performed in two distinct steps. In the first step, we calibrated
the model by simulating in vitro experiments of biochemical degradation of cartilage tissue
explants in the presence of the SM inhibitor. For the purposes of illustration, in this step we
use experimental data for pentosan polysulfate (PPS) inhibiting cartilage degradation [26], and
here assume that the mechanism of action of PPS is by its direct binding to IL-1 (note: by
extending this model, we can later change this model assumption as desired). This model cali-
bration procedure demonstrates how to find the kinetic parameters related to the interaction
of SM with IL-1α.
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Second, we employ this calibrated model to examine the effect of (i) net electrical charge of
the SM and (ii) timing of SM administration, on the inhibition of aggrecan and collagen degra-
dation. Additional parametric studies then investigate the effect of changing the dissociation
constant related to the interaction between the SM and IL-1α. This serves to generalise the
findings of limited experimental data, which is a key advantage of computational modelling.
Model Geometry
Based on our earlier model of cartilage explant degradation [1], we consider a cylindrical carti-
lage explant of diameter 3.0 mm and thickness 1.0 mm. This is consistent with the experimen-
tal data used for model calibration [14]. We assume radial symmetry along the vertical axis of
the explant [1]. Therefore, the cartilage is represented by an axisymmetric two-dimensional
spatial domain with radius (r) of 1.5 mm and thickness (z) of 1.0 mm as shown in Fig 1. The
current model accounts for the effect of electrical charge on Na+, Cl-, IL-1α and SM. These spe-
cies undergo Donnan partitioning between the synovial fluid or support media and cartilage
tissue [12, 41, 42], which has a pre-determined fixed charge density. We include the synovial
fluid or support media in the model. Assuming radial symmetry, the support medium/synovial
fluid is represented by a two-dimensional spatial domain of 0.2 mm thickness (r = 1.5 mm to
1.7 mm and z = 1.0 mm to 1.2 mm) surrounding the cartilage explant as shown in Fig 1. It is
to be noted that the governing equations for the non-charged species are only solved over
the domain representing the cartilage tissue. In contrast, the equations representing the electri-
cally charged species are solved over both the cartilage tissue and the surrounding support
medium/synovial fluid.
Governing equations
As with our earlier model [1], the current model accounts for the transport of IL-1α and its
interaction with the IL-1α receptors present on the surface of the chondrocytes. Proteases
secreted through the IL-1α activation of chondrocytes include aggrecanases and matrix metal-
loproteinases (MMP), which then interact with and degrade the key structural ECM compo-
nents, aggrecan and collagen. The transport and chemical interactions of the non-charged and
the electrically charged species is mathematically represented by the transient Nernst-Planck
equation with a source/sink term representing sources or sinks and chemical reactions:
@Ci
@t
¼ Di;jr
2Ci þ ZiFmi;jCir
2V Ri;j ð1Þ
In Eq (1), suffix ‘i’ denotes the variables representing the non-charged and electrically
charged species in this model. The non-charged species include chondrocyte (‘cell’), intact
aggrecan (‘ag’), degraded aggrecan (‘agd’), intact collagen (‘col’), degraded collagen (‘cold’),
aggrecanase (‘aga’) and MMP (‘mmp’). The electrically charged species include Na+ (‘Na’), Cl-
(‘Cl’), IL-1α (‘IL-1’) and SM (‘d’). Di (m
2/s) and Ci (cells/m
3 or moles/m3) represent the effec-
tive diffusivity and concentration of the ith species, respectively. The source or sink term, Ri
(moles/m3/s) represents the rates of generation or consumption/apoptosis of the respective
species.
The suffix ‘j’ denotes the domains/medium over which the governing equations are solved.
The two media applicable to our model include the support medium/synovial fluid (j = f) and
the cartilage tissue (j = c). Zi denotes the valency or the magnitude of the net electrical charge
of the species ‘i’ and F (C/moles) denotes the Faraday’s constant. For non-charged species, Zi
is set to zero, which effectively converts Eq (1) into a transient reactive-diffusive transport par-
tial differential equation. The parameter μi,j (moles.s/kg) denotes the electrical mobility of
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Fig 1. Schematic of cartilage tissue explant and its adjoining environment containing the inflammatory cytokine IL-1α and the small
molecule (SM). The inflammatory cytokine IL-1α activates biochemical pathways in the cartilage tissue that promote cartilage degradation. The
SM acts to inhibit the biochemical pathways promoting cartilage degradation. Panel A shows the actual cylindrical geometry of the explant (grey)
cultured in a medium (orange) in the presence or absence of the inflammatory cytokine IL-1α and SM. A cylinder concentric (dotted brown outline)
to the cylinder representing the cartilage explant indicates the domain boundary for the computational model. The domain includes both the
cartilage tissue explant and a section representing the support medium. The labels indicate the locations of the bottom (surface 1), curved (surface
2) and top (surface 3) of the cartilage tissue explant. Panel B shows the two-dimensional (2D) representation of the computational domain. The
axis of symmetry is represented by the solid green line. The purple line represents the cartilage tissue explant surface in direct contact with the
bottom surface of the well plate (surface 1). The aqua blue and light green lines represents the curved (surface 2) and top (surface 3) of the
cartilage tissue explant, respectively. The brown, black and pink lines represent the bottom (surface 4), curved (surface 5) and top (surface 6)
surfaces of the domain boundary. The section of the computational domain shaded in grey represents the cartilage tissue explant. The section of
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species ‘i’ in the jth medium. V (mV) denotes the electrostatic potential. The spatial variation
of electrical potential is estimated from the Poisson’s equation, as shown below:
r2V ¼
  rj
ε0εj
ð2Þ
Where ρj (C.m-3) denotes the total space charge density in the jth medium, ε0 is the permittivity
of free space (ε0 = 8.85×10-12farad.m-1) and εj is the relative permittivity of the jth medium. We
assume the relative permittivity of the two media to be equal to that of water [42]. This
assumption is further justified by the fact that approximately 80% of cartilage tissue mass is
made up of water [43, 44]. The charge density of the individual media (ρf and ρc) is calculated
according to Donnan theory [12, 42], which assumes partitioning of the mobile charged spe-
cies between the two phases to achieve electroneutrality in equilibrium. Mathematically, this
can be represented as:
rj ¼ F
X
ZiCi   FCD

ð3Þ
where FCD represents cartilage fixed charge density, which is primarily a function of the local
aggrecan concentration in cartilage [37, 41, 42]. In the support medium/synovial fluid, FCD is
assumed to be zero [41, 45]. The governing equations representing the transport and chemical
interactions of the individual species inside the cartilage and the support medium/synovial
fluid are shown in Table 1 for this modelling study.
the computational domain shaded in orange represents the support medium. The radial and axial co-ordinates of the model geometry are
represented by the symbols r and z, respectively. The horizontal and vertical red arrows indicate the positive direction of the r and z co-ordinate
axis.
doi:10.1371/journal.pone.0168047.g001
Table 1. Model governing equations.
Species/Variables Equation
Chondrocyte (Ccell) @Ccell
@t
¼ Dcellr
2Ccell þ k1Ccell   k2Ccell
Aggrecan (intact) (Cag) @Cag
@t
¼ Dagr
2Cag þ R1Ccell 1  
Cag
Ctar
 
  k3Caga
Cag
CagþKm;aga
 
Aggrecan (degraded) (Cagd) @Cagd
@t
¼ Dagdr
2Cagd þ k3Caga
Cag
CagþKm;aga
 
Stimulus aggrecanase (S1) @S1
@t
¼ a1ðC

  S1Þ
Aggrecanase (Caga) @Caga
@t
¼ Dagar
2Caga þ k4S1   k5Caga
Collagen (intact) (Ccol) @Ccol
@t
¼ Dcolr
2Ccol   kact;mmpk8Cmmp
Ccol
CcolþKm;mmp
 
Collagen (degraded) (Ccold) @Ccold
@t
¼ Dcoldr
2Ccold þ kact;mmpk8Cmmp
Ccol
CcolþKm;mmp
 
Stimulus MMP (S2) @S2
@t
¼ a2ðC

  S2Þ
MMP (Cmmp) @Cmmp
@t
¼ Dmmpr
2Cmmp þ k10S2   k11CmmpCcoldnR;cold
Sodium ion (CNa) @CNa
@t
¼ DNar
2CNa þ ZNaFmNaCNar
2V
Chloride ion (CCl) @CCl
@t
¼ DClr
2CCl þ ZClFmClCClr
2V
IL-1 (CIL-1) @CIL  1
@t
¼ DIL  1r
2C1L  1 þ ZIL  1FmIL  1CIL  1r
2V   k6CIL  1R
CIL  1a
CIL  1aþKm;IL  1
 
  k7CIL  1   k12CIL  1
Cd
CdþKm;d
 
SM (Cd) @Cd
@t
¼ Ddr
2Cd þ ZdFmdCdr
2V   k12CIL  1
Cd
CdþKm;d
 
Electrostatic Potential (V) r2V ¼   rj
ε0εj
doi:10.1371/journal.pone.0168047.t001
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Initial and Boundary Conditions
The initial conditions are shown in Table 2. For intact aggrecan (ag), the initial concentration
in the cartilage tissue is set as a function of the tissue thickness (see Table 2). This is based on
the reported steady state (turnover rates) in vivo aggrecan concentration profiles for young
bovine cartilage explants from computational [1, 39] and experimental [38] studies. We set the
initial concentrations of Na+ and Cl- ions at the reported [41, 42] physiological ionic concen-
tration of 150 moles/m3 in both the cartilage tissue and support medium/synovial fluid.
The boundary conditions are listed in Table 3. The boundary conditions assigned to the
non-charged species are similar to our previous model [1] and include: (i) zero flux boundary
condition at the bottom surface (denoted surface 1) of the tissue explant, (ii) zero flux bound-
ary condition at the curved (denoted surface 2) and top (denoted surface 3) surfaces of the tis-
sue explant for chondrocytes (cell) and intact collagen (col), (iii) Robin boundary conditions
for intact aggrecan (ag), degraded aggrecan (agd) and MMP (mmp) along the curved and top
surfaces of the tissue explant and (iv) Dirichlet type boundary condition for representing the
concentrations of aggrecanase (aga) and degraded collagen (cold) at the curved and top sur-
faces of the explant. A Dirichlet type boundary condition is used to represent the concentra-
tions of the electrically charged species (Na+, Cl-, IL-1α and SM) at the outer boundaries of the
domain (denoted as surface 4, 5 and 6) representing the support medium/synovial fluid. The
concentration of the charged species at these locations equals their bulk concentration in the
plasma. Similar to our earlier model [1], zero flux boundary condition is applied at the bottom
surface of the tissue explant (denoted surface 1) for all the electrically charged species.
For the Poisson’s equation, we assume that all the outer boundaries of the computational
domain representing the support medium/synovial fluid (denoted surface 4, 5 and 6) are elec-
trically grounded (V = 0). The bottom surface of the tissue explant (denoted surface 1) is con-
sidered to be electrically insulated. This is because the resting surfaces of in vitro cartilage
explants cultured in well plates appear to be in direct contact with the plastic well-plate as evi-
denced from histological images of cartilage tissue explants incubated in the presence of
inflammatory cytokines including IL-1α and TNF-α [1, 48, 49]. In certain simulations, some
of the above boundary conditions are rendered time-dependent. The time dependency is
introduced to replicate specific experimental/physiological scenarios simulated by the model.
Details related to specific modifications introduced in the boundary conditions are discussed
in the results section as applicable.
Table 2. Model initial conditions.
Species Values/ Expression (Units) References
Chondrocyte (Ccell) 1.5×1014 (cells/m3) [46]
Intact aggrecan (Cag) (in vitro)   0:0433 z
H
  4
þ 0:0431 z
H
  3
  0:0162 z
H
  2
þ 0:002 z
H
  
þ 0:0242 ðmoles=m3Þ [1, 38]
Degraded aggrecan (Cagd) 0 (moles/m3) [1]
Aggrecanase (Caga) 0 (moles/m3) [1]
Intact collagen (Ccol) 0.2 (moles/m3) [1, 43, 47]
Degraded collagen (Ccold) 0 (moles/m3) [1]
MMP (Cmmp) 0 (moles/m3) [1]
Sodium ion (CNa) 150 (moles/m3) [41, 42]
Chloride ion (CCl) 150 (moles/m3) [41, 42]
IL-1α (CIL-1) 0 (moles/m3) [1]
SM (Cd) 0 (moles/m3) Text
Electrostatic Potential (V) 0 (mV) Text
doi:10.1371/journal.pone.0168047.t002
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Model Parameters
Model parameters are listed in Table 4. The majority of the parameters are sourced from our
earlier computational model for IL-1α mediated cartilage biochemical degradation [1]. These
include i) cartilage explant dimensions, ii) rates of formation and apoptosis of chondrocytes,
iii) rates of intact aggrecan synthesis by chondrocytes, iv) Michaelis-Menten kinetic parame-
ters to represent the catalytic activity of proteases (aggrecanase and MMP), v) rates of forma-
tion of aggrecanase and MMP including parameters from rate equations capturing the time
delay in protease expression, vi) parameters related to the binding kinetics of IL-1α to IL-1
receptors (IL-1R) located on the surface of the chondrocytes and vii) parameters representing
the dependence of aggrecan concentration on MMP activity [1, 50].
Additional model parameters in the current study include those associated with the Nernst-
Planck and Poisson’s equations. The parameters include (i) valency or electrical charge magni-
tude (Zi) of the charged species, (ii) electrical mobility of the charged species in cartilage (μi,c)
and support medium/synovial fluid (μi,f), (iii) relative permittivity of cartilage tissue (εc) and
support medium/synovial fluid (εf), (iv) fixed charge density (FCD) of cartilage tissue and (v)
kinetic parameters related to the SM driven inhibition of IL-1α mediated cartilage degrada-
tion. As mentioned earlier, we initially assume that the SM inhibits cartilage degradation by
directly binding to IL-1α. Hence the rate of binding of IL-1α with the SM is represented by the
turnover number, k12 (s
-1) and the dissociation constant, Km,d (moles/
3). We used Km,d values
ranging from 0.001 μM to 1 μM. This was based on reported dissociation constant data related
Table 3. Model boundary conditions.
Species Surface Mathematical Expression
Chondrocyte 1, 2, 3 DcellrCcell = 0
Intact aggrecan 1 DagrCag = 0
Intact aggrecan 2 DagrCag + hr,ag (Cag − Cag,b)= 0
Intact aggrecan 3 DagrCag + hz,ag (Cag − Cag,b)= 0
Degraded aggrecan 1 DagdrCagd = 0
Degraded aggrecan 2 DagdrCagd + hz,agd (Cagd − Cagd,b)= 0
Degraded aggrecan 3 DagdrCagd + hz,agd (Cagd − Cagd,b)= 0
Aggrecanase 1 DagarCaga = 0
Aggrecanase 2, 3 Caga = 0
Intact collagen 1, 2, 3 DcolrCcol = 0
Degraded collagen 1 DcoldrCcold = 0
Degraded collagen 2, 3 Ccold = 0
MMP 1 DmmprCmmp = 0
MMP 2 DmmprCmmp + hr,mmp (Cmmp − Cmmp,b) = 0
MMP 3 DmmprCmmp + hz,mmp (Cmmp − Cmmp,b) = 0
Sodium ion 1 DNa,crCNa + ZNaμNa,cFCNarV = 0
Sodium ion 4, 5, 6 CNa = CNa,b
Chloride ion 1 DClrCCl + ZClμClFCClrV = 0
Chloride ion 4, 5, 6 CCl = CCl,b
IL-1α 1 DIL-1,crCIL-1 + ZIL−1μIL−1,cFCIL−1rV = 0
IL-1α 4, 5, 6 CIL−1 = CIL−1,b
SM 1 DdrCd,c + Zdμd,cFCdrV = 0
SM 4, 5, 6 Cd = Cd,b
Electrostatic Potential 1 rV = 0
Electrostatic Potential 4, 5, 6 V = 0
doi:10.1371/journal.pone.0168047.t003
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Table 4. Model Parameters.
Parameters Values/Expressions References
Effective diffusivity (Chondrocyte) (Dcell) 0 m2/s [51]
Effective diffusivity (Intact aggrecan) (Dag) 1×10−14 m2/s [52]
Effective diffusivity (Degraded aggrecan) (Dagd)(Cag is in moles/m3) Dagd ¼ Dagde  95Cag [1, 53]
Diffusivity (Degraded aggrecan) (D*agd) 1×10−10 m2/s [52, 54]
Effective diffusivity (Aggrecanase) (Daga) Daga ¼ Dagae  120Cag [1, 53]
Diffusivity (Aggrecanase) (D*aga) 1×10−12 m2/s [55]
Effective diffusivity (Intact collagen) (Dcol) 0 m2/s [54]
Effective diffusivity (Degraded collagen) (Dcold) Dcold ¼ Dcolde  95Cag [1, 53]
Diffusivity (Degraded collagen) (D*cold) 1×10−10 m2/s [52, 56]
Effective diffusivity (MMP) (Dmmp) Dmmp ¼ Dmmpe  95Cag [1, 53]
Diffusivity (MMP) (D*mmp) 1×10−12 m2/s [55, 57]
Effective diffusivity (Na+) (DNa,c) (cartilage) 1.33×10−9 m2/s Text, [58]
Effective diffusivity (Na+) (DNa,f) (fluid)(fluid represents support medium or synovial fluid) 1.33×10−9 m2/s Text, [58]
Effective Diffusivity (Cl-) (DCl,c) (cartilage) 2.03×10−9 m2/s Text, [58]
Effective Diffusivity (Cl-) (DCl,f) (fluid) 2.03×10−9 m2/s Text, [58]
Effective diffusivity (IL-1α) (DIL-1,c) (cartilage) DIL  1 ¼ DIL  1e  95Cag [1, 53]
Diffusivity (IL-1α) (D*IL-1) 7×10−11 m2/s [59]
Effective diffusivity (IL-1α) (DIL-1,f) (fluid) 7×10−9 m2/s text
Effective Diffusivity (SM) (Dd,c) (cartilage) 2.66×10−10 m2/s [12]
Effective Diffusivity (SM) (Dd,f) (fluid) 2.66×10−8 m2/s [12]
Basal aggrecan production rate (R1) Pag 1   0:9zH
   [1]
Target aggrecan (intact) concentration (Ctar) 0.024 moles/m [1, 39]
Chondrocyte based basal aggrecan production (Pag) 2.4×10−22 moles/cell/s [60, 61]
Thickness of cartilage tissue explant (H) 1×10−3 m Text, [1]
Chondrocyte production rate (k1) 0 cells/s [1]
Chondrocyte apoptosis rate (k2) 0 cells/s [1]
Catalytic rate constant (aggrecanase) (k3) 1.45 s-1 Text, [62, 63]
Michaelis constant (aggrecanase) (Km,aga) 8.5×10−5 moles/m3 Text, [63, 64]
Rate constant aggrecanase production (k4) 0.83k6 s-1 [1, 65]
Aggrecanase degradation rate (k5) 1×10−4 s-1 [1, 66]
Turnover number (IL-1α binding to IL-1R) (k6) 4.32×10−5 s-1 [1, 67]
Dissociation constant (IL-1α binding to IL-1R) (Km,IL-1) 7.2×10−8 moles/m3 [1, 67]
IL-1α degradation rate (k7) 5.83×10−4 s-1 [1, 68]
IL-1α receptor concentration (CIL-1R) nRCcell
NA
  [69]
Number of IL-1 receptors in single chondrocyte (nR) 2700 cell-1 [1, 67]
Avogadro number (NA) 6.023×1023 #/moles [69]
Na+ concentration (bulk fluid/support medium/synovial fluid) (CNa,b) 150 moles/m3 Text, [41, 42]
Cl- concentration (bulk fluid) (CCl,b) 150 moles/m3 Text, [41, 42]
IL-1α concentration (bulk fluid) (CIL-1,b) 5.7×10−8 moles/m3 Text, [14]
SM concentration (bulk fluid) (Cd,b) 0.0003 moles/m3 Text, [26]
Catalytic activity (MMP) (k8) 1.5 s-1 [70]
Michaelis constant (MMP) (Km,mmp) 0.0021 moles/m3 [70]
Aggrecan dependent MMP catalytic activity (kact,mmp) bmax
1þ
CagþCagd
k9
 n [1]
Cag+Cagd at half-maximal MMP activity (k9) 0.0003 moles/m3 [1]
Hill–coefficient MMP activity (n) 6 [1]
(Continued )
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to binding of interleukin family of cytokines with their signaling inhibitors including heparin,
canakinumab and rilanocept [5, 24, 73, 74].
Table 4. (Continued)
Parameters Values/Expressions References
Maximum MMP activity (βmax) 1 [1]
Rate constant MMP production (k10) 0.17k6s−1 [1, 65]
Rate constant MMP binding to degraded collagen (k11) 0.47 M-1.s-1 [70]
# of MMP binding sites on degraded collagen (nR,cold) 320 [1]
Turnover number (IL-1α binding to SM) (k12) 1 s-1 Text, [12, 26]
Dissociation constant (IL-1α binding to SM) (Km,d) 1×10−3 moles/m3 Text, [12, 26]
IL-1-IL-1R complex equilibrium concentration (C*) CIL  1CIL  1R
CIL  1þKm;IL  1
 
moles=m3 [71]
Rate constant aggrecanase stimulus (α1) 0.4×10−5 s-1 [1]
Rate constant MMP stimulus (α2) 0.4×10−5 s-1 [1]
Intact aggrecan radial mass transfer coefficient (hr,ag) 1×10−10 m/s [1]
Intact aggrecan axial mass transfer coefficient (hz,ag) 0.8×10−10 m/s [1]
Degraded aggrecan radial mass transfer coefficient (hr,agd) 1.5×10−8 m/s [1]
Degraded aggrecan axial mass transfer coefficient (hz,agd) 1.2×10−8 m/s [1]
MMP radial mass transfer coefficient (hr,mmp) 1×10−9 m/s [1]
MMP axial mass transfer coefficient (hz,mmp) 1×10−9 m/s [1]
Synovial fluid intact aggrecan concentration (Cag,b) 0 moles/m3 [1, 39]
Support medium intact aggrecan concentration (Cag,b) 0 moles/m3 [1]
Support medium degraded aggrecan concentration (Cagd,b) 0 moles/m3 [1]
Support medium MMP concentration (Cmmp,b) 0 moles/m3 [1]
Cartilage fixed charge density (FCD)   200ðCagþCagdÞ
0:024
moles=m3 Text, [37]
Valency/ charge magnitude (Na+) (ZNa) +1 [41]
Valency/ charge magnitude (Cl-) (ZCl) -1 [41]
Valency/charge magnitude (IL-1α) (ZIL-1) -1 [36]
Valency/charge magnitude (SM) (Zd) -16 to +16 Text, [12]
Electrical mobility (general) (μi,j) Di;j
RT
  [72]
Electrical mobility (Na+) (cartilage) (μNa,c) 5.16×10−13 s.moles/kg [41, 72]
Electrical mobility (Na+) (fluid) (μNa,f) 5.16×10−13 s.moles/kg [41, 72]
Electrical mobility (Cl-) (cartilage) (μCl,c) 7.8×10−13 s.moles/kg [41, 72]
Electrical mobility (Cl-) (fluid) (μCl,f) 7.8×10−13 s.moles/kg [41, 72]
Electrical mobility (IL-1α) (cartilage) (μIL-1,c) DIL  1;c
RT
  [72]
Electrical mobility (IL-1α) (fluid) (μIL-1,f) 2.7×10−12 s.moles/kg [36, 72]
Electrical mobility (SM) (cartilage) (μd,c) 1.03×10−13 s.moles/kg [12, 72]
Electrical mobility (SM) (fluid) (μd,f) 1.03×10−11 s.moles/kg Text, [12, 72]
Permittivity (free space) (ε0) 8.85×10−12 farad/m [42]
Relative permittivity (cartilage) (εc) 100×108 Text, [42]
Relative permittivity (fluid) (εf) 100×108 Text, [42]
Faraday’s constant 96500 C/moles [42]
Universal gas constant (R) 8.314 J/mol/K [42]
Temperature (T) 310 K Text
Dissociation constant (SM binding to IL-1R) (K*m,d) 1 μM, 1 nM, 100 pM, 1 pM Text
Dissociation constant (SM binding to ECM) (Km,ECM) 100 nM, 1 μM Text, [12]
doi:10.1371/journal.pone.0168047.t004
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Based on the reported FCD’s [37, 75] and density of cartilage tissue (1.15 g/ml) [43], we esti-
mate the basal FCD of cartilage tissue in the range of -150 to -200 moles/m3. Shapiro et al. [76]
proposed a correlation for calculation of cartilage FCD based on tissue aggrecan concentra-
tion. Using the reported steady state maximum in vivo aggrecan concentration of 0.024 moles/
m3 (assuming molecular weight of aggrecan to be 2.5 MDa [77] in young bovine cartilage [1,
38, 39]), we estimate the cartilage FCD to be -233 moles/m3. For this study, we select the basal
FCD of the cartilage to be -200 moles/m3 corresponding to the steady state tissue aggrecan
concentration of 0.024 moles/m3 and reported mass composition of aggrecan in cartilage tis-
sue [43]. The change in FCD due to spatio-temporal variation in tissue aggrecan concentration
is captured using the correlation shown in Table 4.
Numerical Solution
We solved the governing equations together with the appropriate initial and boundary condi-
tions numerically using the finite element software COMSOL Multiphysics (Version 5.0, Bur-
lington, MA, USA). We performed a mesh dependence study, which showed that beyond
12751 mesh elements, the model predictions are independent of the number of finite elements.
We thus used a total of 12751 quadratic finite elements consisting of 917 boundary elements
for all our simulations. The relative accuracy for the simulations was set at 1×10−3. The simula-
tions were performed on a high end PC (Intel (R) Core i7-4930K CPU @ 3.40 GHz processor
with 64 GB RAM) with simulation times ranging from 30–1200 s.
Results
Model Calibration
This work builds upon our previous model of IL-1α mediated degradation of bovine calf carti-
lage explants [1]. However, this study is significantly different from our earlier model as it
takes into account Donnan partitioning of charged molecules as boundary conditions at the
cartilage-medium interface. This includes incorporating the fixed charge density of cartilage,
the physiological ionic strength of the fluid, and the charge on IL-1α and the SM. These modi-
fications are incorporated into the model through the following steps:
1. Selection of pH and charge on IL-1α. Cartilage has a physiological pH slightly above 7 [78].
We estimated the net charge on IL-1α to be -1 using a protein calculator PepCalc (PepCalc,
Innovagen AB, Lund, Sweden).
2. Fixed charge is estimated first by theoretical calculation based on two moles of negative
charge per mole of chondroitin sulfate disaccharide unit (one sulfate and one carboxyl) [79]
and using the reported molecular weight of 502.5 mg/mmole for a chondroitin sulfate
disaccharide unit [76, 80]. In terms of the total aggrecan concentration, the fixed charge of
the cartilage tissue can be calculated as follows [76]:
FCD ¼
  2ðCag þ CagdÞ
502:5
ð4Þ
where FCD is the fixed charge of the cartilage tissue expressed as mM and Cag and Cagd are
the concentrations of intact and degraded aggrecan expressed in mg/l. We used Eq (4) to
calculate the fixed charge corresponding to the reported range of aggrecan concentration in
young bovine cartilage tissue (55–60 mg/ml) [38]. The calculated fixed charge of the carti-
lage tissue is consistent with reported fixed charge densities for young bovine cartilage tis-
sue [75].
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3. Selection of diffusivities. The effective diffusivity of IL-1α in the cartilage tissue is the same
as our earlier modeling study [1]. The effective diffusivity of Na+, Cl- and SM were obtained
from literature [53, 58]. Though the ‘charge partner’ diffusing with the ion or molecule can
influence the magnitude of the diffusion coefficient [58], we chose the effective diffusivities
of Na+, Cl- and SM to be constant. This is not expected to significantly alter the steady state
and transient results presented here because Na+ and Cl- ion concentrations are much
larger than the SM concentration. Additionally, the molecular weight of Na+, Cl- and SM is
significantly lower compared to aggrecan, collagen, IL-1α and proteases.
We recalibrated the model taking into account Donnan partitioning, by comparing model
predictions with the in vitro time-dependent aggrecan loss data from young bovine cartilage
explants as reported by Li, Wang et al. [14]. These experiments involved culturing of young
bovine cartilage explants in adequate support medium both in the absence and presence of the
inflammatory cytokine IL-1α for a period of 27 days. Practically, this involved the recalibration
of one model parameter (Km,aga) to take into account the reduced concentration of IL-1α in
the cartilage. The Michaelis constant for aggrecanase catalyzed degradation of intact aggrecan
(Km,aga) is reported to range from 11.0 nM to 28.2 μM [63, 64, 81]. The predicted aggrecan loss
from the explant matched the corresponding experimental data [14] as Km,aga is increased by
about 55% from 55 to 85 nM. Hence, the adjusted value of Km,aga remains within its reported
range (i.e. 11.0 nM to 28.2 μM [63, 64, 81]). Fig 2A shows the comparison between the experi-
mental [14] and predicted aggrecan loss profile from the explant.
Because IL-1α is negatively charged at physiological pH, ion exclusion means that the con-
centration for the charged molecule at equilibrium is somewhat lower than for an uncharged
molecule at equilibrium. Fig 2B shows the predicted spatial average IL-1α concentration of the
explant for the different cases simulated during the model calibration process. Interestingly,
the average IL-1α concentration reached a steady-state value of 0.4 ng/ml at 9 days similar to
the predictions from our previous model without Donnan partitioning [1]. The steady state
average concentration of IL-1α in the explant was considerably less than the concentration in
the surrounding media despite ongoing transport into the cartilage. This can be attributed to
the rapid protease induced degradation of IL-1α [68] as accounted for in our previous [1] and
current model.
Donnan partitioning of SM
Donnan partitioning leads to the inclusion or exclusion of molecules by the cartilage tissue
depending on the fixed charge of the cartilage tissue and net charge of the molecule [12, 80].
We thus used our model to investigate the effect of the SM electrical charge on the: (i) time-
dependent uptake of SM from synovial fluid into cartilage tissue and (ii) time-dependent
release of SM post-removal of SM from the surrounding media. To study the SM uptake and
release kinetics, we simulated a 1D geometry, as the 1D model geometry approximates the in
vivo drug delivery scenario.
Fig 3 shows the schematic of the model geometry. The depth of the cartilage tissue for the
1D model is set at 1.5 mm, which is consistent with measured in vivo depth for young bovine
knee cartilage [53, 82]. The concentration of intact aggrecan within the cartilage tissue is set at
a spatially-uniform constant value of 60 mg/ml (0.024 moles/m3). We solve the governing
equations representing the transport of electrically charged species simultaneously with the
Poisson’s equation (Eq (3)). For the purposes of simplicity, we assume the molecular weight of
the SM to be 3 kDa for all simulations. Additional simulations were performed assuming the
molecular weight of the SM as 10 kDa. The effective diffusivity of the small molecule in the car-
tilage tissue was set at a constant value of 2.6×10−10 m2/s. This is consistent with measured
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diffusivities of electrically charged molecules (MW = 3 to 10 kDa) across young bovine carti-
lage tissue explants [12]. The following boundary conditions are used for the 1D model:
1. We set the concentrations of Na+ and Cl- to 150 moles/m3 at the outer boundary of the
domain representing the synovial fluid (outer). This is based on the reported serum concen-
tration [83] and serum/synovial fluid distribution ratio [84] for sodium chloride. The con-
centration of the SM is set at 1 μg/ml (i.e. 0.0003 moles/m3). This however changes to
0.0001 moles/m3 for a 10 kDa molecule.
2. During simulation of the SM release process, the concentration of SM at the outer bound-
ary of the computational domain (outer) is set to zero, while concentrations of Na+ and Cl-
remain unchanged from the model simulating the SM uptake process.
3. For both the uptake and release simulations, a zero flux boundary condition is set for all the
species at the boundary representing the osteochondral junction (inner). The outer bound-
ary of the computational domain representing the synovial fluid (outer) is assumed to be
electrically grounded (V = 0 mV), while the boundary representing the osteochondral junc-
tion (inner) is assumed to be electrically insulated.
Fig 4 shows the predicted average concentration of SM (C^d) in the cartilage tissue for nega-
tively charged SM during the uptake (Fig 4A and 4B) and release (Fig 4C and 4D) process. The
results show that exposure of the cartilage tissue to the SM leads to an initial period of SM
uptake by the cartilage tissue. This is indicated by the time-dependent increase in the average
concentration of SM in the cartilage tissue. Subsequently, the average tissue SM concentration
reaches a steady-state value indicating equilibration of the electrochemical potential between
the cartilage tissue and the synovial fluid. The time required for the average SM concentration
in the cartilage tissue to reach 50% of the steady-state value (t50,U) range from 0.6 hours (Zd =
-16) to 1.1 hrs (Zd = -1). The corresponding steady-state average SM concentration in the carti-
lage tissue range from 0.0007 μg/ml (Zd = -16) to 0.5 μg/ml (Zd = -1). The results from the
desorption simulations show an instantaneous release of SM from the cartilage tissue into the
Fig 2. Temporal variation in aggrecan loss from tissue and tissue based IL-1α concentration for
young bovine cartilage explants subjected to in vitro IL-1αmediated biochemical degradation. Panel
A shows the comparison between the predicted and experimental [14] rate of aggrecan loss from the explant.
Panel B shows the temporal variation in the spatial average concentration of IL-1α of the cartilage explant.
The model is calibrated by adjusting the Michaelis constant for aggrecanase catalyzed degradation of intact
aggrecan (Km,aga). The calibrated model accounts for the electrochemical interactions of IL-1α in the support
medium and in the cartilage tissue.
doi:10.1371/journal.pone.0168047.g002
Fig 3. Schematic of the 1D model geometry representing the cartilage tissue and its surrounding media containing synovial fluid. The
computational domain includes both the cartilage tissue and a section representing the synovial fluid. The solid red line (outer) represents the outer
boundary of the computational domain. The solid green line represents the osteochondral junction (inner). The section of the computational domain
shaded in grey represents the cartilage tissue explant. The section of the computational domain shaded in orange represents the synovial fluid. The
spatial co-ordinate of the model geometry is represented by the symbol r. The horizontal brown arrow indicates the positive direction of the r co-
ordinate axis.
doi:10.1371/journal.pone.0168047.g003
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Fig 4. Effect of electrical charge on the in vivo uptake and retention of negatively charged SM in cartilage tissue. Panel A shows the uptake
kinetics of negatively charged SM by the cartilage tissue. Panel B represents the enlarged version of Panel A for net SM charge of -16, -10 and -8. The
bulk concentration of SM in the plasma (Cd,b) is assumed to be 1 μg/ml during the uptake process (Cref = 1 μg/ml). Panel C shows the release kinetics
of negatively charged SM from cartilage tissue into the synovial fluid. Panel D represents the enlarged version of Panel C for net SM charge of -16, -10
and -8. The bulk concentration of SM in the plasma (Cd,b) is assumed to be 0 μg/ml during the release process. Zd denotes the valency or net charge of
the SM. The time required for the average SM concentration in the cartilage tissue to reach 50% of the steady-state value during the uptake process is
denoted as t50,U. The time required for the SM concentration to reach 50% of the initial value during the release process is denoted as t50,R. The
molecular weight of the SM is assumed to be 3 kDa for these simulations. The concentration of intact aggrecan throughout the cartilage tissue is set at
a constant value of 60 mg/ml.
doi:10.1371/journal.pone.0168047.g004
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synovial fluid. This is indicated by the time-dependent reduction in the average SM concentra-
tion of the cartilage tissue. The release of SM from the cartilage tissue continues till all the SM
partitioned from synovial fluid to cartilage tissue during the uptake process is depleted. The
time required for the SM concentration to reach 50% of the initial value during the release pro-
cess (t50,R) range from 0.6 hours (Zd = -16) to 1.1 hours (Zd = -1) (i.e. similar to the rate for
uptake). The results from this analysis demonstrate that the negative fixed charge of the carti-
lage results in exclusion of negatively charged molecules (anion) from the cartilage ECM.
Fig 5 shows the predicted average concentration of SM (C^d) in the cartilage tissue for posi-
tively charged SM during the uptake (Fig 5A) and release (Fig 5B) process. The uptake and
release kinetic profiles are similar to the negatively charged SM. However, the predicted equili-
bration times are considerably longer while the steady-state average SM concentration in carti-
lage tissue are significantly higher for positively charged SM. The time required for average
SM concentration to reach 50% of the steady-state value (t50,U) during SM sorption ranged
from 3 hours (Zd = +1) to over 38 days (Zd = +16). The corresponding steady-state average SM
concentration in the cartilage tissue range from 2.0 μg/ml (Zd = +1) to 1953.4 μg/ml (Zd =
+16). The time required for the SM concentration to reach 50% of the initial value during the
release process (t50,R) range from 3 hours (Zd = +1) to 62 days (Zd = +16). The results from
this analysis demonstrate that the negative fixed charge of the cartilage causes inclusion of pos-
itively charged molecules into the cartilage ECM (cation inclusion) from synovial fluid. We
also note that the time for cation uptake to reach equilibrium is considerably longer than the
time required for anion uptake to reach equilibrium.
Model calibration for inhibition of IL-1αmediated cartilage degradation
by the SM
Our next step is to model the inhibition of the IL-1α mediated degradation of the cartilage tis-
sue. To do this, we first assume that the SM inhibits IL-1α mediated cartilage degradation by
directly binding to IL-1α. We take into account the mass action reaction kinetics of the SM
and IL-1α interaction. Km,d represents the dissociation constant related to binding of IL-1α to
SM. We tried three values of the dissociation constant (Km.d), namely, 10 nM (Case 1), 100 nM
(Case 2) and 1 μM (Case 3). We selected these cases based on reported dissociation constants
related binding of interleukin family of cytokines with their corresponding inhibitors [5, 24,
73, 74]. We assume a net charge of -1 on IL-1α (at physiological pH) and -16 on the SM. The
molecular weight of the SM is assumed to be 3 kDa.
Fig 6A shows the predicted rate of aggrecan loss from cartilage tissue explant for cases 1, 2
and 3, which are compared with the predicted aggrecan loss profile in the absence of chemical
interaction between IL-1α and SM (Base Case) (4 curves). For reference, the experimental
aggrecan loss data from young bovine cartilage explants in the presence and absence of IL-1α
are also shown (2 curves) [14]. Fig 6B and 6C show the spatial average concentration of intact
aggrecan (C^ag) and IL-1α (C^IL-1) for the four cases simulated. The results demonstrate that
chemical interaction between SM and IL-1α significantly reduced the IL-1α mediated catabo-
lism of intact aggrecan. In comparison to the base case, the aggrecan loss from the explant is
reduced by 75%, 64% and 37% for cases 1 (Km.d = 10 nM), 2 (Km.d = 100 nM) and 3 (Km.d =
1 μM), respectively at 27 days (Fig 6A and 6D).
The predicted aggrecan loss profile from the explant corresponding to Km,d of 1 μM (Case
3) is similar to the reported [26] in vitro aggrecan loss from bovine cartilage explants cultured
in the presence of 1 μM retinoic acid and 1 μg/ml pentosan polysulfate (PPS) (note: though
only the aggrecan loss profiles upon exposure to retinoic acid are shown, the paper says IL-1α
has aggrecan loss profiles similar to that of retinoic acid, as confirmed in a later paper by
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Fig 5. Effect of electrical charge on the in vivo uptake and retention of positively charged SM in cartilage tissue. Panel A shows the uptake
kinetics of positively charged SM by the cartilage tissue. Panel B represents the enlarged version of Panel A for net SM charge of +4, +2 and +1. The
bulk concentration of SM in the plasma (Cd,b) is assumed to be 1 μg/ml during the uptake process (Cref = 1 μg/ml). Panel C shows the release kinetics
of positively charged SM from cartilage tissue into the synovial fluid. Panel D represents the enlarged version of Panel C for net SM charge of +4, +2
and +1. The bulk concentration of SM in the plasma (Cd,b) is assumed to be 0 μg/ml during the release process. Zd denotes the valency or net charge
of the SM. The time required for the average SM concentration in the cartilage tissue to reach 50% of the steady-state value during the uptake
process is denoted as t50,U. The time required for the SM concentration to reach 50% of the initial value during the release process is denoted as t50,R.
The molecular weight of the SM is assumed to be 3 kDa for these simulations. The concentration of intact aggrecan throughout the cartilage tissue is
set at a constant value of 60 mg/ml.
doi:10.1371/journal.pone.0168047.g005
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Fig 6. Effect of inhibition of IL-1αmediated degradation of cartilage tissue by SM. Panel A shows the effect of the rate of inhibition of IL-1α by SM
on the predicted rates of aggrecan losses from the cartilage tissue. The predicted rates of aggrecan loss are compared with in vitro aggrecan loss data
from young bovine cartilage explants in the absence (control) and presence of IL-1α [14]. Km,d represents the dissociation constant of binding of IL-1α
and the SM. The model was simulated at three distinct values of the dissociation constant (Km.d) including 10 nM (Case 1), 100 nM (Case 2) and 1 μM
(Case 3). The chemical interaction between IL-1α and SM is not accounted for in the ‘Base Case’ scenario. Panel B and Panel C show the temporal
variation in the spatial average intact aggrecan and IL-1α concentration of the cartilage explant for the different cases simulated. Panel D shows the
effect of Km,d on the extent of aggrecan loss from the cartilage tissue at 27 days after initial exposure to IL-1α. The net charge on IL-1α and SM are
assumed to be -1 and -16, respectively. The molecular weight of the SM is assumed to be 3 kDa.
doi:10.1371/journal.pone.0168047.g006
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Munteanu et al. [85]). Our results also show that the rate of aggrecan loss from cartilage tissue
for case 1 (Km,d = 10 nM) is consistent with reported in vitro aggrecan loss data from bovine
cartilage explants cultured in the absence of any aggrecan catabolic agents [14, 26] i.e. a Km,d =
10 nM results in a similar profile to the control case, even when exposed to IL-1α [14]. The
computational modelling shows that the steady-state average IL-1α concentration of the
cartilage tissue reduced by 99%, 98% and 94% corresponding to case 1 (Km,d = 10 nM), case 2
(Km,d = 100 nM) and case 3 (Km,d = 1 μM) compared to the base case. For all further analysis,
Km,d is assumed as 1 μM.
The net charge on SM regulates the rate of IL-1αmediated cartilage
degradation
Next we investigated the effect of the net SM charge on the inhibition of IL-1α mediated degra-
dation of cartilage tissue. We investigated specific net charge magnitudes ranging from -16 to
+16 (Zd = -16, -8, +8 and +16, respectively). We assume a net charge of -1 on IL-1α (at physio-
logical pH). The molecular weight of the SM is assumed to be 3 kDa. The simulation results
appear in Fig 7. The results show that a positively charged SM can significantly reduce the rate
of aggrecan loss from cartilage tissue compared to a negatively charged SM. An increase in the
net SM charge magnitude from -16 to -8 causes a 38% reduction in aggrecan loss from the car-
tilage tissue at 27 days (Fig 7A and 7D). This is further reflected by the temporal variation in
spatial average concentration of IL-1α (C^IL-1) in the cartilage tissue, shown in Fig 7C. For net
SM charge of -16, the spatial average IL-1α concentration of the explant increases from zero to
a maximum value of 0.07 ng/ml at 3 days. Subsequently, the IL-1α concentration reduces to
reach a steady state concentration of 0.02 ng/ml at 9 days. In contrast to net SM charge of -16,
the spatial average IL-1α concentration of the explant reaches a steady state value of 0.02 ng/
ml at 3 days corresponding to the net SM charge of -8.
The model also predicts that an increase in the net charge of SM from -8 to +4, eliminates
aggrecan catabolism. The rate of aggrecan loss from the explant at net SM charge of +4 and
above (Zd = +8 and +16) (see Fig 7A and 7D), is consistent with reported in vitro aggrecan loss
data from bovine cartilage explants cultured in the absence of IL-1α [14], that is, the spatial
average aggrecan concentration in the cartilage tissue reduced by only 5% for positively
charged SM (Fig 7B). As shown in Fig 7C, the spatial average concentration of IL-1α in the
explant reduced by an order of magnitude for positively charged SM. Overall, these results
show that positively charged SM may completely inhibit the IL-1α mediated aggrecan catabo-
lism in cartilage tissue.
Timing of SM administration on the inhibition of IL-1αmediated cartilage
degradation
Our next step is to examine the effect of delaying SM administration on the inhibition of IL-1α
mediated degradation of cartilage tissue. Hence we simulated five cases: (i) Case 1: the simulta-
neous administration of SM with IL-1α, (ii) Case 2: administration of SM 12 hours after initial
exposure to IL-1α, (iii) Case 3: administration of SM 24 hours after initial exposure to IL-1α,
(iv) Case 4: administration of SM 3 days after initial exposure to IL-1α and (v) Case 5: adminis-
tration of SM 6 days after initial exposure to IL-1α. The time delay between the appearance of
IL-1 and the administration of SM is denoted td.
For these simulations we assume a net charge of -1 on IL-1α (at physiological pH) and -16
on the SM. Again the molecular weight of the SM is assumed to be 3 kDa. Simulation results
appear in Fig 8. Surprisingly, the computational model results show that the SM can efficiently
inhibit IL-1α mediated degradation of cartilage tissue as long as the SM is administered within
Modeling Inhibition of IL-1 Mediated Cartilage Degradation
PLOS ONE | DOI:10.1371/journal.pone.0168047 December 15, 2016 20 / 38
Fig 7. Effect of net charge of SM on inhibition of IL-1αmediated aggrecan catabolism in cartilage tissue. Panel A shows the effect of net SM
charge (Zd) on the predicted rates of aggrecan losses from the cartilage tissue. The predicted rates of aggrecan loss are compared with in vitro
aggrecan loss data from young bovine cartilage explants in the absence (control) and presence of IL-1α [14]. The model was simulated for net SM
charge magnitudes (Zd) of -16, -8, +16 and +8. Panel B and Panel C show the temporal variation in the spatial average intact aggrecan and IL-1α
concentration of the cartilage explant for the different cases simulated. Panel D shows the effect of net SM charge on the extent of aggrecan loss from
the cartilage tissue at 27 days following initial exposure to IL-1α. The net charge on IL-1α is assumed to be -1 and the molecular weight of the SM is
assumed to be 3 kDa. The dissociation constant related to binding of IL-1α to SM (Km,d) is assumed to be 1 μM.
doi:10.1371/journal.pone.0168047.g007
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Fig 8. Effect of timing of SM administration on the inhibition of IL-1αmediated cartilage degradation. Panel A shows the effect of timing of SM
administration post initial tissue exposure to IL-1α (td) on the predicted rates of aggrecan losses from the cartilage tissue. The predicted rates of
aggrecan loss are compared with in vitro aggrecan loss data from young bovine cartilage explants in the presence of IL-1α [14]. The model was
simulated at five distinct values of td including 0 days (Case 1), 0.5 days (Case 2), 1 day (Case 3), 3 days (Case 4) and 6 days (Case 5). Panel B and
Panel C show the temporal variation in the spatial average intact aggrecan and IL-1α concentration of the cartilage explant for the different cases
simulated. Panel D shows the impact of SM administration timing (td) on the extent of aggrecan loss from the cartilage tissue at 27 days for the different
cases simulated. The net charge on IL-1α and SM are assumed to be -1 and -16, respectively. The molecular weight of the SM is assumed to be 3 kDa.
The dissociation constant related to binding of IL-1α to SM (Km,d) is assumed to be 1 μM.
doi:10.1371/journal.pone.0168047.g008
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24 hours (1 day) following initial exposure of cartilage to IL-1α (Fig 8A). The average intact
aggrecan and IL-1α concentration of the cartilage tissue are shown in Fig 8B and 8C. For case
1, the IL-1α concentration gradually increases with time to reach a maximum value of 0.07 ng/
ml at 3 days. Following 3 days, the IL-1α concentration gradually reduces with time to reach a
steady state value of 0.02 ng/ml at 9 days for cases 1, 2 and 3. The temporal variation in the spa-
tial average concentration of intact aggrecan in the cartilage tissue is similar for cases 1, 2 and
3. However, intact aggrecan concentrations in the cartilage tissue were almost 10% lower if the
SM is administered 3 days after initial exposure of the cartilage tissue to IL-1α (case 4).
For cases 2 and 3, the IL-1α concentration reaches its maximum value of 0.1 ng/ml over 3
to 12 hours and then drops to a value of 0.07 ng/ml at 3 days. However, the high IL-1α concen-
tration in the cartilage tissue over 3 to 12 hours does not significantly impact the aggrecan deg-
radation due to the time delay involved in the expression of aggrecanase following binding of
IL-1α to IL-1 receptors [1, 86]. So if this is ‘shunt-down’ within 24 hours, aggrecanase produc-
tion does not have the opportunity to become fully established. In contrast, administration of
the SM after 72 hours (3 days) of exposure of the cartilage to IL-1α (Case 4) results in a 10%
increase in aggrecan loss from cartilage tissue relative to cases 1, 2 and 3. The increase in aggre-
can loss can be attributed to greater availability of IL-1α in the cartilage tissue between 3 to 6
days (Fig 8C), and so greater opportunity for production of aggrecanase to become established.
We also see that that administration of the SM after 144 hours (6 days) of exposure of the carti-
lage to IL-1α (Case 5) results in a 45% increase in aggrecan loss from cartilage tissue in com-
parison to cases 1, 2 and 3 (Fig 8D), as aggrecanase production is comparatively high. Thus
our results show that there exists a window of opportunity of 24 hours for administration of
aggrecan catabolic inhibitors to effectively arrest the IL-1α mediated degradation of cartilage
tissue before it becomes established.
Competitive inhibition of IL-1αmediated cartilage degradation by SM
So far our model results are based on the assumption that the SM inhibits cartilage degradation
by directly binding to IL-1α. However, there are several inhibitors of IL-1 signaling, which act
by binding to IL-1 receptors (IL-1R) [2, 5, 74]. In other words, such inhibitors directly compete
with IL-1 for binding to IL-1R [74]. In this section, we model competition between IL-1 and
the SM for the IL-1 receptor.
In the absence of any inhibitor, the fraction of total IL-1R bound by IL-1α under equilib-
rium condition is given by [71]:
C

CIL  1R
¼
CIL  1
CIL  1 þKm;IL1
ð5Þ
However, the presence of an inhibitor capable of binding to IL-1R (e.g. the SM in our case)
may significantly reduce the fraction of total IL-1R bound by IL-1α [87]. This can be mathe-
matically represented as [71, 87]:
C

CIL  1R
¼
CIL  1
CIL  1 þKm;IL1 1þ
Cd
Km;d
  ð6Þ
where Km,d in Eq (6) represents the dissociation constant related to binding of the SM to IL-
1R. Eq (6) is based on the assumption that the total concentration of IL-1α, SM and IL-1R in
particular are constant [71] similar to our earlier model [1].
We implement the competitive inhibition of IL-1α mediated cartilage degradation in our
model by substituting Eq (6) into the model governing equations of IL-1α and the stimulus
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responses representing the time delay in the expression of aggrecanase and MMP (S1 and S2).
We assume a net charge of -1 for IL-1α and -16 for SM. The molecular weight of the SM is
assumed to be 3 kDa. We selected the molecular weight and charge of the SM based on the
reported molecular weight and isoelectric point of known osteoarthritis inhibitors including
pentosan polysulfate (PPS) [12, 88, 89]. We simulated the model for four values of Km,d includ-
ing 1 μM (Case 1), 1 nM (Case 2), 100 pM (Case 3) and 1 pM (Case 4). We selected these values
based on the kinetic parameters related to the binding of IL-1α to IL-1R and the total IL-1R con-
centration (see Table 4). We compare the results from these cases with the predicted aggrecan
loss profile in the absence of any chemical interaction between the SM and IL-1R (Base Case).
The simulation results are shown in Fig 9. The results show that the inhibition efficiency of
the SM in mitigating IL-1α mediated aggrecan catabolism is negligible for cases 1 (Km,d =
1 μM) and 2 (Km,d = 1 nM) (Fig 9A). In fact competitive inhibition of cartilage degradation
by the SM is completely ineffective at dissociation constant of 1 μM for binding of the SM to
IL-1R, which stand in contrast to the small molecule binding directly to IL-1α. In order for the
SM to be effective at large dissociation constants (e.g. 1 μM), it is necessary that the SM be pos-
itively charged. We find that (results not shown) the SM with a net charge of +16 could
completely inhibit IL-1α mediated aggrecan catabolism at Km,d = 1 μM. Hence, the effective-
ness of competitive inhibition of IL-1α mediated cartilage degradation is primarily dependent
on Donnan partitioning of the SM from surrounding media to the cartilage tissue.
For case 3 (Km,d = 100 pM), the aggrecan loss from the explant is reduced by about 33%.
For case 4 (Km,d = 1 pM), IL-1α mediated aggrecan catabolism is completely inhibited, as the
predicted aggrecan loss data from cartilage tissue is consistent with reported in vitro aggrecan
loss data from bovine cartilage explants cultured in the absence of IL-1α [14, 26]. This is con-
firmed by the spatial average aggrecan concentration in the cartilage tissue (Fig 9B), which
reduced by 96%, 90%, 57% and 17% at 27 days for cases 1 (Km,d = 1 μM), 2 (Km,d = 1 nM), 3
(Km,d = 100 pM) and 4 (K

m,d = 1 pM), respectively. The results indicate that the ability of a
molecule to competitively inhibit IL-1α mediated cartilage degradation depends strongly on
its binding affinity with IL-1 receptors present on the chondrocyte surface, as otherwise con-
centrations of the small molecule need to be unrealistically high. Fig 10 shows that an increase
in the binding affinity between SM and IL-1R (indicated by reduction in Km,d) decreases the
fraction of total IL-1R bound by IL-1α.
Discussion
It is commonplace for various small molecules to be charged [12, 31, 90]. In the case of carti-
lage tissue, charge is particularly important because cartilage tissue has an unusually large neg-
ative fixed charge due to the high concentration of aggrecan [12, 41], which influences the
uptake of charged molecules. The purpose of the computational models developed in this
study is to assess the way an electrically charged small molecule influences cartilage degrada-
tion by binding to the inflammatory cytokine IL-1α. To do this, it is helpful to first consider
Donnan partitioning of the SM between the synovial fluid and cartilage tissue alone. The
results from our models (specifically the 1D model) have shown that in the absence of any size
exclusion, Donnan partitioning may have a profound effect on the concentration distribution
of any electrically charged species in the cartilage tissue and surrounding medium. Negatively
charged molecules tend to be excluded from the cartilage tissue (known as ‘anion exclusion’),
while positively charged molecules are drawn into the cartilage (known as ‘cation inclusion’).
Assuming no interaction with the cartilage extracellular matrix, our models show that the time
scales for the uptake and release of the SM are similar for any given specific net charge, as
shown in Figs 4 and 5.
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Specifically we observe that the time scales for the uptake and release of negatively charged
molecules into a cartilage tissue of 1.5 mm thickness occurs on the order of hours. For exam-
ple, the uptake and release times for a 3 kDa molecule with net charge of -16, -8 and -1 are 0.6,
0.8 and 1.1 hours, respectively. This is much the same for a 10 kDa small molecule. In contrast,
the time scales for uptake and release of positively charged molecules are considerably longer,
and range from hours to days. For example, the uptake (t50,U) and release (t50,R) times for a 3
kDa MW molecule with net charge of +1 is 3 hours, and for a 10 kDa MW molecule with a net
charge of +8 is 2–3 days. However, the uptake and release times for a 10 kDa MW molecule
with net charge of +16 is longer (t50,U = 42 days and t50,R = 72 days) in comparison to a 3 kDa
MW molecule with the same net charge (t50,U = 38 days and t50,R = 62 days).
The MW dependent variation in the uptake and release times of molecules with net charge
of +16 is due to the smaller diffusion coefficient of the 10 kDa molecule and the lower concen-
tration of the drug in the synovial fluid (0.0001 moles/m3) [91]. Importantly, the total SM par-
titioning uptake for positively charged molecules by the cartilage tissue is about 1 to 3 orders
of magnitude higher than that for negatively charged molecules of similar charge magnitude.
Therefore, the partitioning storage of positively charged small molecules in cartilage ECM is
substantial, which increases their duration of pharmacological action in cartilage tissue.
These SM uptake results are consistent with in vitro experiments designed to compare the
uptake kinetics of NeutrAvidin with Avidin into young bovine cartilage tissue [12]. While
these molecules are considerably larger than 3 kDa (MW = 66 kDa), and so size exclusion may
apply to some degree [12], the total uptake of positively charged Avidin is reported to be
approximately 400 fold higher in comparison to its neutral counterpart [12], which is broadly
consistent with the theoretical predictions reported here. We also note in passing that Avidin
was reported to demonstrate weak reversible binding with the cartilage ECM (Km,ECM =
150 μM) [12]. The higher retention duration of positively charged molecules within the carti-
lage tissue may be advantageous therapeutically. For example, Avidin has been used as a carrier
for drugs to modify cartilage degradation [12, 90].
The suitability of a drug to be used as an inhibitor of IL-1α mediated cartilage degradation
depends on: (i) the concentration of the drug in the cartilage tissue, (ii) the dissociation con-
stant (Km,d) related to binding of IL-1α to the drug and (iii) the uptake kinetics and the resi-
dence time of the drug in the cartilage tissue. We also note that for constant therapeutic effect,
drug concentration may be ‘traded-off’ with the dissociation constant. It has been reported
that IL-1α levels in synovial fluid increases significantly following traumatic injury to cartilage
tissue [14, 92, 93]. The results presented here show that even small molecules with a very
strong negative charge (MW = 3 kDa and Zd = -16) can completely inhibit IL-1α mediated
aggrecan catabolism provided it binds strongly to IL-1α with a dissociation constant of 10 nM
or smaller (see Fig 6 and Table 5). Furthermore, even a SM with a net charge of -16 and a Km,d
of 1 μM can reduce cartilage degradation by about 30%, provided it is administered within a
window of 24 hours following initial exposure of the cartilage tissue to IL-1α (see Fig 8 and
Fig 9. Effect of inhibition of IL-1αmediated degradation of cartilage tissue by binding of SM to IL-1
receptors (IL-1R). Panel A shows the effect of binding affinity of SM to IL-1R on the predicted rates of
aggrecan losses from the cartilage tissue. The predicted rates of aggrecan loss are compared with in vitro
aggrecan loss data from young bovine cartilage explants in the absence (control) and presence of IL-1α [14].
K*m,d represents the dissociation constant related to binding of SM to IL-1R. The model was simulated at
three distinct values of the dissociation constant (K*m,d) including 1 μM (Case 1), 1 nM (Case 2) and 1 pM
(Case 3). The chemical interaction between the SM and IL-1R is not accounted for in the ‘Base Case’ scenario
(no inhibition of IL-1αmediated cartilage degradation by the SM). Panel B shows the temporal variation in the
spatial average intact aggrecan concentration of the cartilage explant for the different cases simulated. The
net charge on IL-1α and SM are assumed to be -1 and -16 respectively. The molecular weight of the SM is
assumed to be 3 kDa.
doi:10.1371/journal.pone.0168047.g009
Modeling Inhibition of IL-1 Mediated Cartilage Degradation
PLOS ONE | DOI:10.1371/journal.pone.0168047 December 15, 2016 26 / 38
Table 6). This highlights that a strong negative charge can be offset by a small dissociation
constant. We note in passing that a dissociation constant of 10 nM is well above the reported
dissociation constant of 30 pM for binding of IL-1α to the decoy IL-1α receptor, IL-1RII
[18, 94, 95].
Clearly if the charge and concentration of a molecule in cartilage tissue is known or can be
computed, then it is possible for our IL-1α induced cartilage degradation model to be used to
infer the dissociation constant for binding of IL-1α to SM (Km,d). To illustrate the application
Fig 10. The fraction of total IL-1 receptors (IL-1R) bound by IL-1α under equilibrium condition in the presence of a SM (which
is a competitive inhibitor of IL-1α). The parameter K*m,d represents the dissociation constant related to binding of the SM to IL-1R.
CIL-1R represents the concentration of the total IL-1 receptors. C* represents the concentration of the IL-1-IL-1R complex formed due to
binding of IL-1αwith IL-1R. The concentration of the SM for the different binding constants (K*m,d) examined is set at a fixed value of
1 μg/ml. The ‘Control’ legend refers to the fraction of total IL-1 receptors (IL-1R) bound by IL-1α under equilibrium condition in the
absence of SM.
doi:10.1371/journal.pone.0168047.g010
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of the model to experimental data, we consider Munteanu et al. [26], who reported on IL-1
induced degradation of cartilage (aggrecan loss), with and without pentosan polysulfate (PPS).
PPS was used at 1 μg/ml in the bathing solution. If we make the reasonable assumption that
the molecular weight of PPS was about 3 kDa and had a net charge of -16 (PPS is highly sul-
fated [96, 97]), and if we further assume that PPS binds directly to IL-1α, then the predicted
aggrecan loss profiles are consistent with PPS binding to IL-1 with a Km,d of 1 μM.
The binding coefficient required of small inhibitory molecules is considerably increased
when the small molecules have a positive charge. Our results show that a small molecule that
binds to IL-1α with a comparatively large dissociation constant of 1 μM, can completely inhibit
IL-1α mediated aggrecan catabolism, provided the SM is positively charged (Fig 7 and
Table 7). The complete inhibition of IL-1α mediated aggrecan catabolism under these condi-
tions can be attributed to the higher concentration of SM in cartilage tissue due to cation inclu-
sion. We note that a prolonged pharmacological action can be obtained when the small
molecule has a large positive charge, as the time for release of the SM from cartilage tissue is
extended (see Fig 5C). However, positively charged small molecules also take a longer time to
achieve equilibrium with the cartilage tissue (see Fig 5A). Further, positively charged molecules
may not only partition to cartilage ECM, but may also reversibly bind to the ECM [12]. Fig 11
shows our simulation results for the extended 1D model simulating the in vivo drug delivery
scenario, taking into account the drug binding to the cartilage ECM. It is clear that binding of
the SM to the cartilage ECM increases the steady-state average SM total concentration in the
cartilage tissue by an order of magnitude. Additionally, the release times of the SM from the
cartilage tissue are very significantly increased, which prolongs their duration of pharmacolog-
ical action in cartilage tissue.
For molecules that are cleared quickly from the bathing solution (e.g. small molecules in
synovial fluid have a half-life of about 1–4 hours [40, 98–100]), a large positive charge will
maximise uptake into the tissue in the time prior to clearance, as has been confirmed experi-
mentally [12, 40]. Small molecules with net charge of +8, +10 and +16 partition ‘upwards’
Table 5. Impact of IL-1α-SM binding kinetics for a SM (MW = 3 kDa, with a net charge of -16) on IL-1α
mediated cartilage degradation rates.
Km,d (nM) Aggrecan Loss (27 days)
1 24.0%
10 25.0%
50 30.5%
100 35.3%
1000 62.0%
Experiment (IL-1α) [14] 96.0%
Experiment (Control) [14] 22.0%
doi:10.1371/journal.pone.0168047.t005
Table 6. Impact of timing (td) of SM (MW = 3 kDa, Zd = -16 and Km,d = 1 μM) administration on IL-1α
mediated cartilage degradation rates.
td (days) Aggrecan Loss (27 days)
0 62.0%
0.5 62.0%
1 62.0%
3 67.0%
6 88.2%
doi:10.1371/journal.pone.0168047.t006
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from the synovial fluid to cartilage tissue with partitioning ratio (C^i,c/C^i,f) of approximately 6
within 4 hours as shown in Fig 5A, while the release may then take days. For example, after 4
hours of uptake, the time required for the average SM concentration to reach 50% of the initial
average concentration during the release process (t50,R) are 2, 6 and 79 days corresponding to
net SM charge of +8, +10 and +16 (results not shown). Hence, IL-1α inhibitor molecules are
most effective in arresting cartilage degradation, when: (i) the molecule is small (preferable
MW = 3–5 kDa) (ii) it has a large positive charge and (iii) it binds strongly to IL-1α and so has
a small dissociation constant (e.g. 10 nM or below).
However, in addition to partitioning and binding of positively charged molecules to the car-
tilage ECM, other methods may be employed to sustain the inhibition of IL-1α mediated carti-
lage degradation including: (i) conjugation of OA drugs with positively charged carriers [12,
90] and (ii) encapsulation of OA drugs in particles and a particle based drug delivery system,
which includes pastes [101, 102]. Conjugating OA drugs with positively charged carriers are
reported to significantly increase their uptake and retention duration in cartilage tissue [12,
90]. Though these conjugated molecules are usually much larger than the SM reported here,
these results are consistent with our model predictions (see Fig 5). The model developed here
can be extended to model both conjugation and encapsulation.
The computational analysis to examine the effect of SM administration on the inhibition of
cartilage degradation assumes that the SM binds with IL-1α to directly block the catabolic
action of IL-1α. However, the SM may also interact with: (i) any of the molecules in the IL-1
and IL-1R families, and (ii) with downstream targets within the cell, or on molecules secreted
by the cell [2, 74, 97]. For example, anakinra binds to the IL-1R [2]. This interaction may be
incorporated into the present model by including competitive interaction between IL-1α and
anakinra for the IL-1 receptor. Similarly it has been shown that PPS may exert its principal
protective action in cartilage by inhibiting the activity of proteases (aggrecanases and MMPs)
and not by binding to IL-1α directly [97, 103]. In this case, the model can be modified to incor-
porate the PPS dependent activity of aggrecanases and MMPs. In this way, the basic model
presented here may be extended to include the large variety of possible SM interactions,
depending on its intended purpose.
To illustrate how the model may be adjusted, we have examined the mechanism of competi-
tive interaction between IL -1α and the SM for the IL-1 receptor. The results show that the
binding coefficient required for a negatively charged SM (Zd = -16) to competitively inhibit
cartilage degradation ranges from 1–10 pM (Km,d = 1–10 pM). This is significantly lower
compared to direct inhibition by binding of the SM to IL-1α (Km,d = 1–10 nM) (see Figs 6 and
9). To view this in another way, for the same binding constant of 1 μM, the SM is much less
effective at inhibiting cartilage degradation when it competitively binds to IL-1R than when it
binds to IL-1 directly (compare Figs 6 and 9). The observed difference between the two inhibi-
tion mechanisms can be attributed to: (i) the strength of the binding coefficient related to the
Table 7. Impact of SM (MW = 3 kDa, with a dissociation constant of 1 μM for binding to IL-1α) electrical
charge (Zd) on IL-1αmediated cartilage degradation rates.
Zd Aggrecan Loss (27 days)
-16 62.0%
-8 38.5%
-4 28.7%
+4 24.2%
+8 24.0%
+16 23.7%
doi:10.1371/journal.pone.0168047.t007
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Fig 11. The in vivo uptake and retention of positively charged SM in cartilage tissue in the absence (‘Control’) and presence of SM binding
to cartilage ECM. Panel A and Panel B shows the uptake and release kinetics of a small molecule with a net charge of +1 by the cartilage tissue.
Panel C and Panel D shows the uptake and release kinetics of a small molecule with a net charge of +4 by the cartilage tissue. The parameter Km,ECM
represents the dissociation constant related to the binding of the small molecule (SM) to the cartilage ECM. C^d,total represents the spatial average total
concentration of the drug in the cartilage tissue including the free drug concentration (C^d) and the drug bound to the cartilage ECM (C^d,bound). The bulk
concentration of SM in the plasma (Cd,b or Cref) is assumed to be 1 μg/ml during the uptake process. The bulk concentration of SM in the plasma (Cd,b)
is assumed to be 0 μg/ml during the release process. The molecular weight of the SM is assumed to be 3 kDa for these simulations. The concentration
of intact aggrecan throughout the cartilage tissue is set at a constant value of 60 mg/ml.
doi:10.1371/journal.pone.0168047.g011
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binding of IL-1α to its receptor (Km,IL1 = 72 pM) and (ii) the total IL-1 receptor concentration
CIL-1R = 0.7 nM, which is an order of magnitude higher than the maximum concentration of
IL-1α (1 ng/ml). Hence the total fraction of IL-1 receptors bound by IL-1α drops from 86% to
3% as Km,d reduces from 1 μM to 1 nM as also illustrated in Fig 10.
However, there are some model limitations. The dissociation constant for binding between
IL-1α and SM can be mathematically expressed as follows:
Km;d ¼
CIL  1Cd
Ccomp
ð7Þ
In Eq (7) both IL-1α and SM are charged species. Assuming that the support medium/syno-
vial fluid has a neutral pH, we can re-write Eq (7) within the cartilage tissue in terms of the
synovial fluid/support medium concentrations of IL-1α and SM and the potential difference
between synovial fluid/support medium and cartilage tissue (ΔV) as follows:
Km;d ¼
CIL  1;fe
  ZIL  1FDV
RT
   
Cd;fe
  ZdFDV
RT
   
Ccomp
ð8Þ
The above equation indicates that Donnan partitioning may influence the distribution of
both IL-1α and the SM. However, the valency (Zi) for the SM and IL-1α may also be influenced
by the pH, which is itself also a function of Donnan partitioning. Hydrogen ions also partition
due to the electrochemical gradient existing between the surrounding medium/synovial fluid
and cartilage tissue. The pH of the surrounding medium/synovial fluid is around 7.2 [104]. It
has also been reported that the pH of the cartilage tissue is approximately neutral at the surface,
becoming somewhat acidic with depth (average pH is about 6.7 in normal cartilage). This is
due to the increasing negative fixed charge with depth [38, 41, 105], together with the avascular
nature of cartilage tissue, which favours anaerobic metabolism [78, 106]. Hence positively
charged hydrogen ions are partitioned towards the negatively charged cartilage tissue. Using a
Donnan partitioning ratio of 1.8 for species with net charge of +1 (Na+) as predicted by our
model, we estimate the pH difference between the cartilage tissue and surrounding medium to
be approximately 0.2 units. As this is reasonably small, the assumption of a constant pH of 7.0
for both the cartilage and surrounding medium appears to be a reasonable approximation for
our analysis above. However, the assumption of Zi being independent of pH could be relaxed
for more accurate analyses.
Conclusions
In this study, we have extended our previous model of IL-1α mediated degradation of bovine
calf cartilage explants [1] to include the effects of (i) the negative fixed charge of the cartilage
tissue and (ii) the Donnan partitioning of electrically charged species including IL-1α from the
synovial fluid/support medium to the cartilage tissue. The goal of this study was to identify the
key characteristics of an electrically charged small molecule (MW = 3–10 kDa), which can be
used to effectively inhibit IL-1α mediated cartilage degradation. Our results show that even
negatively charged small molecules (MW = 3 kDa, Zd = -16) can inhibit IL-1α mediated carti-
lage degradation if administered within a stipulated timeframe following initial exposure of
the cartilage tissue to IL-1α. Our analysis shows that even a small molecule with a negative
charge of -16 binding directly to IL-1α with a dissociation constant of 1 μM, can preserve the
cartilage collagen content and restore cartilage structural homeostasis if administered within a
period of six days following initial tissue exposure to IL-1α. Furthermore, the depletion of
aggrecan levels in cartilage tissue due to IL-1α exposure is completely restored in three weeks
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following administration of the small molecule (Fig 8B). However, when the small molecule
competitively inhibits IL-1α by binding to its receptor, then to achieve a similar level of effi-
cacy in protecting against cartilage degradation, the binding coefficient for the small molecule
needs to be between 3 and 4 orders of magnitude smaller. This example highlights the relative
efficacy of inhibiting signaling molecules rather than their receptors.
We also observed that positively charged small molecules can completely inhibit aggrecan
catabolism (Fig 7). The suitability of positively charged small molecules for use as inhibitors of
cartilage degradation can be attributed to (i) their higher uptake by cartilage tissue and (ii)
their longer residence time in the cartilage tissue following uptake. However, even a strong
negatively charged small molecule may be effective if the dissociation constant for binding to
IL-1α is sufficiently small.
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